content

Leading Pulmonologists in India have started using Molnupiravir for mild COVID-19 cases; consider it the best bet for early treatment of COVID-19

With questions being raised on the safety of the only availableย approved oral antiviral pill for COVID-19 - Molnupiravir, health experts of the country have...

Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2, including Omicron

Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent...

Symbiosis announces expansion of capabilities with BSL-2 manufacturing upgrade

Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, has announced an expansion of...

Catalent Increases Specialized Packaging Capabilities at its Philadelphia Facility to Support Growing Biologic and Cell and Gene Therapy Market

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across...

Delta Cargo approves the new Envirotainer Releye RLP container for fleet usage

Delta Cargo announced that it has approved the Envirotainer Releye RLP for usage on their fleet of aircraft. Envirotainer is the global market leader...

Bayer and Mammoth Biosciences to collaborate on novel gene editing technology

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and...

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read